California Public Employees Retirement System decreased its stake in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 11.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 14,323 shares of the biotechnology company’s stock after selling 1,808 shares during the period. California Public Employees Retirement System owned 0.06% of Eiger Biopharmaceuticals worth $147,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in EIGR. Lindbrook Capital LLC bought a new position in Eiger Biopharmaceuticals in the 3rd quarter valued at about $36,000. Citadel Advisors LLC bought a new stake in shares of Eiger Biopharmaceuticals during the second quarter worth approximately $3,168,000. Cubist Systematic Strategies LLC bought a new stake in shares of Eiger Biopharmaceuticals during the second quarter worth approximately $179,000. Cormorant Asset Management LP bought a new stake in shares of Eiger Biopharmaceuticals during the second quarter worth approximately $12,190,000. Finally, Algert Global LLC grew its position in shares of Eiger Biopharmaceuticals by 63.2% in the second quarter. Algert Global LLC now owns 28,770 shares of the biotechnology company’s stock valued at $305,000 after purchasing an additional 11,136 shares during the last quarter. Institutional investors and hedge funds own 76.23% of the company’s stock.
NASDAQ EIGR opened at $13.19 on Friday. The firm has a 50-day moving average price of $11.56 and a two-hundred day moving average price of $10.93. Eiger Biopharmaceuticals Inc has a 12-month low of $8.81 and a 12-month high of $15.33. The company has a market capitalization of $323.09 million, a P/E ratio of -3.45 and a beta of 1.06. The company has a quick ratio of 6.83, a current ratio of 6.83 and a debt-to-equity ratio of 0.44.
A number of brokerages have recently weighed in on EIGR. BidaskClub upgraded Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, November 28th. Zacks Investment Research downgraded Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. ValuEngine upgraded Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. Finally, LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Eiger Biopharmaceuticals in a report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Eiger Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $28.67.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Read More: 52-Week Highs and Lows
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.